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ORIGINAL ARTICLE
Ocular Manifestations and Visual Outcomes of
Behçet’s Uveitis in a Thai population
Kessara Pathanapitoon, MD, PhD1, Paradee Kunavisarut, MD1, Fa-Arun Saravuttikul, MD1, and
Aniki Rothova, MD, PhD2
1Department of Ophthalmology, Faculty of Medicine, Chiang Mai University, Thailand and 2Department of
Ophthalmology, Erasmus Medical Centre, Rotterdam, The Netherlands
ABSTRACT
Purpose: To report on ocular manifestations and visual outcomes of Thai patients with Behçet’s Uveitis (BU).
Methods: We reviewed medical records of 50 BU patients (31 males and 19 females). Ocular manifestations,
treatment modalities, complications, and visual outcomes were registered.
Results: Ocular involvement was bilateral in 76% of patients, resulting in 89 affected eyes. Panuveitis and
posterior uveitis were the most common types. Retinal vasculitis was noted in majority of affected eyes and
specifically arteritis was noticed in 32/57(56%). Most patients received combination therapy of systemic corti-
costeroids and immunosuppressive agents (azathioprine 72%). At final visit, VA ≤20/200 was observed in 25
affected eyes (28%). Risk factors for poor visual outcome were poor visual acuity at presentation (p < 0.001) and
development of optic atrophy (p = 0.01).
Conclusions: Typical ocular manifestations of Thai patients with BU consisted of bilateral uveitis affecting
posterior eye segment with high rate of complications and frequent visual loss.
Keywords: Behçet’s uveitis, complications, ocular manifestations, Thailand, visual outcomes
Behçet’s disease (BD) is a chronic, relapsing, systemic
vasculitis of unknown etiology. Major sites of inflam-
mation are the mucous membranes, skin, and the eyes.
Behçet’s Uveitis (BU) is typically characterized by
recurrent episodes of posterior or panuveitis with
occlusive retinal vasculitis. BU can lead to permanent
vision loss and to various complications that arise
either as a consequence of the inflammation and/or
of its treatment.1 Long-term treatment with systemic
corticosteroids, immunosuppressive agents as well as
with novel biological drugs has been recommended to
prevent the recurrent inflammation and visual loss.1–3
BU has a higher prevalence in the Mediterranean,4
Far and Middle Eastern countries.5,6 In Asia, BU was
reported from Japan,7,8 Korea,9 Taiwan,10 China,11and
India.12 The prevalence of Behçet’s disease in uveitis in
Southeast Asia is not known. In Thailand, Behçet’s
disease was accounting for the cause of uveitis in
about 6%13; however there are no data available on
the clinical features and visual outcomes of BU in our
country. Herein, we report on ocular manifestations,
treatment modalities, complications and visual out-
comes in BU patients in Thai population.
METHOD
We retrospectively reviewed medical records of 50 BU
patients (89 affected eyes) who had been treated in the
uveitis clinic at Chiang Mai University Hospital
between January 2006 and June 2016. All patients
were classified according to the guidelines of
International Study Group (ISG) for Behçet’s disease.14
Medical records were reviewed for demographic
data, location of uveitis at presentation, laterality,
visual acuity (VA) at onset and at final visit, treatment
modalities and development of the ocular complica-
tions as elevated intraocular pressure (IOP
>25 mmHg) and/or glaucoma, optic atrophy, retinal
complications including cystoid macular edema,
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macular hole, macular scar and epiretinal membranes
and retinal detachment (RD). RD was further classified
into tractional, exudative, and rhegmatogenous RD
(RRD).
Each patient underwent a full ophthalmic examina-
tion, including slit lamp biomicroscopy, tonometry
and indirect ophthalmoscopy. Additional examina-
tions as fluorescein angiography (n = 20) and optical
coherence tomography (n = 42) were performed when
required. Uveitis was classified according the anatomic
localization recommended by the standardization
uveitis nomenclature (SUN) working group.15
The term visual impairment was defined as VA of
<20/70 and blindness was defined as VA of ≤20/200
and/or a central visual field of <10 degrees.16
Statistical analysis was performed using descriptive
statistical analysis with SPSS (version 16 software). We
used Pearson ×2 test or Fisher’s exact test for catego-
rical variables. Logistic regression analysis was also
performed. p values of <0.05 were considered statisti-
cally significant.
RESULTS
Our study included 50 BU patients (89 affected eyes).
There were 31 males and 19 females with a male:
female ratio of 1.6:1. The mean age at onset of uveitis
was 33 ± 9 years (range 9 to 56 years). The mean
follow-up time was 48 ± 36 months (range from 3 to
120 months) (Table 1). No differences in the mean age
at the onset of uveitis was noted between genders
(male = 31.5 ± 9.7; range 9–56 years; female = 36 ± 8.7;
range 19–48 years (p = 0.09)).
Bilateral ocular involvement was present in 38/50;
76% patients. Panuveitis and posterior uveitis were the
most common ocular presentations, followed by inter-
mediate and anterior uveitis with no difference
between male and female patients. Retinal vasculitis
was seen in 64% (57/89) of affected eyes and
specifically arteritis was noticed in 32/57; 56%. VA at
presentation of≤20/200 was found in 39% (35/89) of
affected eyes.
The majority of patients (41/50; 82%) received a
combination of oral corticosteroids and immunosup-
pressive agents including azathioprine (88%; 36/41),
methotrexate (27%; 11/41) and cyclosporine (24%; 10/
41). Six patients were treated with oral corticosteroids
alone and three patients treated with oral corticoster-
oids, immunosuppressive agents, and infliximab.
One or more of ocular complications developed in
41/50 (82%) patients (79/89; 89% of affected eyes;
Table 2) and complication rate was 0.2 per person-
year. We found no difference between genders in
development of complications (male 24/31 versus
female 17/19; Pearson Chi-Square p = 0.282).
Cataract and macular lesions were the most frequent
complications, occurring in 65% and 52% of affected
eyes, respectively. RD was present in 4 of 89 eyes
(4.5%); of those, an exudative RD was diagnosed in 2
of 4 eyes, and RRD in 2 of 4 eyes.
One or more surgeries were required in 34 of 89
eyes (38%). Cataract surgery was the most common
surgery performed (97%; 33/34) followed by pars
plana vitrectomy (32%; 11/34) and trabeculectomy
(26%; 9/34).
Patients with posterior uveitis developed more
complications compared to non-posterior uveitis (11/
12 versus 39/77; Pearson Chi-Square p = 0.008) and
patients who had been treated with oral corticoster-
oids alone developed more complications compared to
regimens including also immunosuppressive drugs
(3/6 versus 38/44; Pearson Chi-Square p = 0.03).
Optic atrophy developed more frequently in
patients older than 40 years compared to younger
population (11/21 versus 11/68; Pearson Chi-Square
p < 0.001). Logistic regression analysis showed that
patients older than 40 year had 5.7× more chances of
developing optic atrophy (p < 0.001; 95% CI, 1.95–
16.6).
TABLE 1. General characteristics of Behçet’s uveitis in Thai patients.
Characteristic Number of patients N = 50
Male-to-female ratio 1.6:1
Mean age at onset (±SD; range; years) 33 ± 9 (9–56)
Mean duration of follow up (±SD; range; months) 48 ± 36 (3–120)
Anatomical location of uveitis
• Anterior 7 14%
• Intermediate 7 14%
• Posterior 16 32%
• Panuveitis 20 40%
Laterality
Bilateral 38 76%
Unilateral 12 24%
Blindness in at least one eye at final visit (at average follow-up of 48 months) 22 44%
Blindness in both eyes at final visit (at average follow-up of 48 months) 4 8%
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At final visit, VA of ≤20/200 in 25 affected eyes
(28%) and VA of ≥20/70 in 33 eyes (37%).Bilateral
blindness was found in 4 patients (8%). No difference
in blindness was noted between males and females
(13/31 versus 9/19 Fisher’s Exact Test p = 0.81).The
risk factors for developing a blind eye included VA at
presentation of ≤20/200 (p < 0.001) and development
of optic atrophy (p = 0.01). Logistic regression analysis
showed that patients with VA at presentation of ≤20/
200 had 17× more chances of developing a blind eye
(p < 0.001; 95% CI, 4.4–69.9)] and patients with optic
atrophy had 5× more chances of developing a blind
eye (p = 0.01; 95% CI, 1.4–21.0)].
DISCUSSION
Our study demonstrates that complications and lim-
ited visual outcomes were common in in Thai patients
with BU. Furthermore, we show that complications
were more common in patients treated with corticos-
teroids solely compared to regimens including also
immunosuppressive drugs. Patient with poor VA at
presentation and who developed optic atrophy had a
greater risk of having at least 1 blind eye.
The ocular manifestations of BU in Thai patients were
similar to the previous reports as BU occurred more fre-
quently in males, the involvement of posterior eye seg-
ment was typical and retinal vasculitis was observed in
majority of patients.4,6,9-11 Ocular complications in BU are
diverse and include commonly cataract (15–77%), ocular
hypertension (14–31%) or glaucoma (19%), macular
edema (25–44%), epiretinal membrane (10–17%) and
optic atrophy (8–24%) and RD (1.4–11%).4,6,11 In our ser-
ies, almost all of the affected eyes (89%) developed at least
one complication. This could be due to the late initial
presentation to ophthalmologist, recurrent inflammation
and long-term use of corticosteroids together with the
limited availability of the new immunomodulatory
drugs. Patients with posterior uveitis developed more
complications compared to non-posterior uveitis
(p = 0.008).This illustrates a more severe character of BU
with posterior segment involvement and might be also
related to the need of more aggressive corticosteroids
therapy leading to higher prevalence of glaucoma and
cataract. Prevalence of cataract of 65% (58/89) is similar
to the results from China (75%), 11 but much higher than
from Saudi Arabia, where prevalence of cataract in BU
was reported to be 15%with a follow-upof 8 years.6 In our
series, optic atrophy and macular scars were the major
causes of irreversible complications. We found no differ-
ence in development of complications and blindness
between genders, whilst Turkish and Taiwan studies
reported a significantly higher proportion of complica-
tions in male patients.4,10(Table 3).
Study from two referral centers in England and in
Australia found that male sex, unilateral disease, and
left eye involvement increased the risks of severe
visual loss at 5 and 10 years.17 Another study from
Japan indicated a significant association between poor
visual outcome and having more than three inflamma-
tory attacks per year, severe vitreous opacities and
exudates within the retinal vascular arcades.18 In our
series, we found that also poor visual acuity at pre-
sentation and development of optic atrophy was the
risk factors of poor visual outcomes.
Our study, in which oral corticosteroids and immu-
nosuppressive therapy were the primary management
of BU patients and only very limited number of
patients used biologic drugs, we found that VA
improved in 11% of patients, 28% developed blind
eye and less than 50% of patients had VA better than
20/70.Higher rate of complications was observed in
patients who had been treated with oral corticoster-
oids alone compared to patients receiving also immu-
nosuppressive drugs (p = 0.03). This observation
underlines the need for immunosuppressive medica-
tions in BU and suggests than monotherapy with
TABLE 2. Ocular complications of Behçet’s uveitis per eye (at average follow-up of 48 months).
Complications Number of eyes (N = 89) (%)
Total number of eyes with at least one complication 79 (89)
Cataract 58 (65)
Macular complications 46 (52)
● Cystoid macular edema 11 (24)
● Macular hole 2 (4)
● Macular scar 14 (30)
● Epiretinal membrane 17 (37)
Retinal detachment (RD) 4 (4)
● Exudative RD 2 (50)
● Rhegmatogenous RD 2 (50)
Choroidal detachment 2 (2)
Optic atrophy 22 (25)
Ocular hypertension (IOP >25 mmHg) 19 (17)
Glaucoma 14 (16)
Blind eyes 25 (28)
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corticosteroids is not adequate. Previous studies in
pre-biologics era demonstrated that the visual prog-
nosis in BU was generally poor with prevalence of
blindness of 20–50%,2,4,10,11,17,19–22 which are similar
to our results. Interestingly, the rate of complications
was much higher in our BU patients compared to
Saudi Arabia, despite the similar usage of biologic
drugs.6 This difference might be explained by a higher
prevalence of late stages in our predominantly rural
population. The high prevalence of cataract (65% vs
15% in Saudi Arabia) might be speculatively
explained by a higher dose or longer duration of cor-
ticosteroid medication. In addition, the choice of spe-
cific immunosuppressive agents can also play a role,
as cyclosporine was more often used in Saudi Arabia
than in Thailand (74% vs 20%). Cyclosporine might be
associated with a better control of inflammation in BU
than azathioprine, which was mainly used in our
series. In Thailand, the availability of expensive med-
ications is limited and available only for scarce
patients. Treatment with biologics, given either as
monotherapy or as add-on therapy, improved the
visual prognosis with prevalence of blindness of less
than 10%.2,3
Limitations of our study include its retrospective
character, limited number of patients with variable
follow-up time and a possible selection bias towards
more severe cases, but this is relevant to all studies
from tertiary referral centers.
In conclusion, our study demonstrates that BU in a
Thai population is characterized by posterior or panu-
veitis commonly associated with retinal vasculitis
(especially arteritis) and a high rate of complications
and frequent visual loss.
TABLE 3. Summary of previous reports on clinical features of Behçet’s uveitis.
Country
(Year) Present Turkey4 2004 China11 2006 Taiwan10 2008 Korea9 2015 Saudi Arabia6 2015
Number of patients 50 880 437 227 56 132
(Number of eyes) (89) (1567) (691) (414) (83) (232)
Male:Female 1.6:1 2.1:1 2.7:1 1.6:1 1.4:1 3.4:1
Mean follow-up time (years) 4 NA 4 4 2 8
Mean age at onset of uveitis (years) 33 30 30 31 34 37
Location of uveitis
• Anterior 14% 11%* 3% in males
17% in females
7%* 17%* 8%
• Intermediate 14% NA NA NA 0 3%
• Posterior 32% 29%* NA 22%* 28%* NA
• Panuveitis 40% 60%* 76% in males
50% in females
69%* 55% * 89%
Retina vasculitis (eyes) 64% 89% 32% NA NA 52%
Complications (eyes)
• Cataract 65% 38.5% 77.4% NA NA 15%
• Elevated intraocular pressure 21% 13.8% 31.4% NA NA NA
• Glaucoma 16% NA NA NA NA 19%
• Macular edema 12% 44.5% 38.2% NA 25% NA
• Epiretinal membrane 19% 17% 9.6% NA NA NA
• Optic atrophy 25% 23.6% 16.2% NA NA 8.2%
• Retinal detachment (RD) 4% 1.4% 10.7% NA NA 9.4%
• Exudative RD 50% NA 87% 50%
• Tractional RD 0 30% 41%
• Rhegmatogenous RD 50% 14% 9%
Treatment
• Oral corticosteroids 94% 80% NA 53% 78% 93%
• Immunosuppressive agents
• Azathioprine 72% 30% NS(most common
cyclosporine and
chlorambucil)
11% NA 49%
• Cyclosporine 20% 10% 31% 27% 74%
• Methrotrexate 22% 0 5% NA 5%
• Cyclophosphamide 0 28% 7% NA 0
• Chlorambucil 0 2% 4% NA 0
• Biologics 6% 0 0 0 9%
Visual acuity at final visit
≤20/200 of affected eyes
28% 16% 20% 20% NA 22%
*Per eye
NA: not available; NS: non specific
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